A Long-term Trial of EB-1020 in Adult Patients With ADHD

Inclusion Criteria:

• Participants who completed the treatment period andfollow-up period in the precedingdouble-blind parent Trial (Trial 405-102-00112) and did not meet the criteria fordiscontinuation of the investigational medicinal product (IMP).

• Participants who have not been found to have major problems with trial requirements,such as compliance with the IMP, in the preceding double-blind parent trial.

Exclusion Criteria:

• Participants who are pregnant or breastfeeding or test positive for pregnancy onbaseline visit.

• Participants who started prohibited concomitant medications/therapies for ADHD orother comorbidities at the end of the follow-up period of the preceding trial, orparticipants for whom starting treatment is deemed beneficial.

• Participants who have a significant risk of committing suicide in the opinion of theinvestigator or subinvestigator, or based on the following evidence:

• Active suicidal ideation as evidenced by an answer of "yes" on Questions 4 or 5on the section of suicidal ideation on the since last visit version of theColumbia-Suicide Severity Rating Scale (C-SSRS) in the preceding double-blindparent trial or

• Reported suicidal behavior

• Participants who were found to have serious or severe adverse events that werejudged to be related to the IMP in the preceding double-blind parent trial.

• Participants who test positive for drugs or alcohol in a urine test on baselinevisit.